Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 99

Results For "EMA"

2799 News Found

Coveris ramps up security label protection to tackle retail theft and supply-chain protection
Packaging | August 21, 2024

Coveris ramps up security label protection to tackle retail theft and supply-chain protection

Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur


Health Ministry assures doctors of all possible efforts to ensure safety
Policy | August 19, 2024

Health Ministry assures doctors of all possible efforts to ensure safety

A committee to be formed to suggest measures for ensuring the safety of healthcare professionals


CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance
News | August 19, 2024

CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance

The emergence of new infections in India is a growing concern


Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP
News | August 19, 2024

Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP

This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers


Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer
Drug Approval | August 17, 2024

Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer

Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone


Apollo Hospitals Chennai reaches 6,000+ successful robotic procedure
News | August 16, 2024

Apollo Hospitals Chennai reaches 6,000+ successful robotic procedure

The robotic surgery program has continually pushed the boundaries of medical technology


Pfizer and BioNTech update on mRNA-based combination vaccine program against Influenza and Covid-19
News | August 16, 2024

Pfizer and BioNTech update on mRNA-based combination vaccine program against Influenza and Covid-19

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives